# Cardiol Therapeutics Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Cardiol Therapeutics Inc.). ## Overview Cardiol Therapeutics Inc. is a life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for heart disease. Its programs center on CardiolRx™, an oral cannabidiol formulation, and CRD-38, a subcutaneously administered drug candidate, with development activity primarily in Canada and the United States. ## Products & services • CardiolRx™ oral therapy for inflammatory heart disease • ARCHER clinical program in acute myocarditis • MavERIC clinical program in recurrent pericarditis • CRD-38 subcutaneous drug formulation in development - **CardiolRx™** (45%) — Oral anti-inflammatory therapy being studied for cardiac inflammatory diseases such as myocarditis and pericarditis. - **ARCHER program** (15%) — Clinical development program evaluating CardiolRx™ in acute myocarditis. - **MavERIC program** (20%) — Clinical development program evaluating CardiolRx™ in recurrent pericarditis. - **CRD-38** (20%) — Subcutaneously administered drug formulation under development for cardiovascular inflammation and fibrosis. - CardiolRx™ oral therapy for myocarditis and pericarditis - ARCHER Phase II clinical program in acute myocarditis - MavERIC Phase III clinical program in recurrent pericarditis - CRD-38 subcutaneous formulation in preclinical/clinical development ## Customers Cardiol Therapeutics does not sell into a broad commercial customer base in the traditional sense; its primary counterparties are clinical trial investigators, research institutions, contract research organizations, and regulators involved in drug development. If and when its therapies reach commercialization, the ultimate end users would be patients with inflammatory heart disease and the physicians who treat them. - **Clinical trial sites** (primary) — Hospitals and research centers that enroll patients into ARCHER and MavERIC because they enable the clinical evidence base. - **Cardiology specialists** (primary) — Physicians and investigators who assess and treat myocarditis or pericarditis and help define clinical endpoints. - **Contract research partners** (secondary) — CROs, laboratories, and advisory providers that support trial operations, data collection, and regulatory documentation. - **Future patients** (emerging) — Patients with acute myocarditis or recurrent pericarditis who would ultimately use approved therapies. - Clinical trial sites enrolling myocarditis and pericarditis patients - Investigators and cardiology specialists running study protocols - Contract research and development partners supporting trials - Regulators and ethics boards reviewing development programs - Future patients with inflammatory heart disease ## Geography The company is headquartered in Canada and reports to U.S. and Canadian capital markets, with corporate administration based in Oakville, Ontario. Its clinical development footprint is concentrated in North America, particularly the United States, where the MavERIC phase III network has been expanded, and Canada, where the company is domiciled and conducts corporate functions. - **Canada** (50%) — Headquarters and core corporate operations - **United States** (50%) — Clinical development and investor market exposure - Headquartered in Oakville, Ontario, Canada - Corporate filings and administration are centered in Canada - Clinical trial network includes multiple U.S. sites - North American footprint matters for trial recruitment and oversight - Dual listing links the company to U.S. and Canadian investors ## Strategy Cardiol’s strategy is to advance clinical evidence for its heart-disease programs through late-stage trials and expand its trial network to support enrollment. The company is positioning its platform around differentiated anti-inflammatory and anti-fibrotic mechanisms in diseases with limited approved treatment options, while maintaining optionality with a second formulation candidate in CRD-38. - **Complete and expand clinical trials** (short-term) — Late-stage clinical data are the main driver of value in a development-stage biotech company. - **Strengthen regulatory and scientific package** (medium-term) — Robust clinical evidence is required to support future regulatory filings and partnering discussions. - **Advance pipeline optionality** (medium-term) — A second candidate can broaden the company's development base beyond one lead program. - Advance late-stage clinical programs in myocarditis and pericarditis - Expand U.S. trial sites to support enrollment and execution - Build evidence for CardiolRx™ as a differentiated cardiac therapy - Develop CRD-38 as a second product candidate - Maintain a portfolio anchored in heart-disease inflammation ## Risks Cardiol’s value creation depends on clinical success, so trial outcomes, enrollment speed, and regulatory feedback are the central risks. As a development-stage biotech, it also faces funding risk, dilution risk, and execution risk tied to outsourced research, manufacturing, and clinical operations. - **Clinical trial failure** [critical] — Lead programs depend on positive safety and efficacy data in small, specialized patient populations. - **Enrollment and site activation delays** [high] — Rare or acute cardiac conditions can be difficult to recruit and operationally complex to study. - **Financing and dilution** [high] — Development-stage biotech companies typically rely on external capital before commercialization. - **Regulatory and approval risk** [high] — Even positive trial data may not translate into approval if regulators request additional evidence. - Clinical trial failure could materially impair program value - Enrollment delays can slow milestones and increase development risk - Regulatory uncertainty remains high for novel heart-disease therapies - Funding needs may require equity issuance and dilution - Outsourced trial and manufacturing execution can create quality risk ## Accounting The company’s financial reporting is dominated by research and development costs, clinical trial-related judgments, and share-based compensation rather than product revenue. Investors should watch estimates around accrued trial costs, related-party advisory services, and fair-value measurement of equity awards, all of which can move reported results materially in a development-stage biotech. - **Research and development accruals** — Can change quarterly R&D expense and liabilities - **Share-based compensation** — Affects operating expense and earnings without cash outflow - **Related-party transactions** — Can influence perceived governance and expense classification - **Clinical development milestone timing** — Quarterly R&D volatility - R&D accruals depend on estimates of trial work performed - Related-party advisory costs affect period expense recognition - Share-based compensation is a major non-cash expense - Clinical development milestones can create uneven quarterly costs - As a biotech, asset impairment and going-concern judgments matter --- *Last updated: 2026-09-28T11:58:10.477360+00:00*